The stock of SELLAS Life Sciences Group Inc (SLS) has seen a 11.28% increase in the past week, with a 35.63% gain in the past month, and a 97.27% flourish in the past quarter. The volatility ratio for the week is 10.68%, and the volatility levels for the past 30 days are at 8.41% for SLS. The simple moving average for the last 20 days is 21.06% for SLS’s stock, with a simple moving average of 66.71% for the last 200 days.
Is It Worth Investing in SELLAS Life Sciences Group Inc (NASDAQ: SLS) Right Now?
SLS has 36-month beta value of 2.29. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy”, 1 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for SLS is 97.67M, and currently, short sellers hold a 19.35% ratio of that float. The average trading volume of SLS on July 08, 2025 was 2.70M shares.
SLS stock’s latest price update
SELLAS Life Sciences Group Inc (NASDAQ: SLS)’s stock price has dropped by 0.00% in relation to previous closing price of $2.17. Nevertheless, the company has seen a gain of 11.28% in its stock price over the last five trading days. globenewswire.com reported 2025-07-07 that NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the addition of Linghua Wang, MD, PhD, to its Scientific Advisory Board (SAB). Dr. Wang is a widely respected leader in cancer research and translational science, and she joins the Company’s SAB shortly after the appointments of Philip C. Amrein, MD, and Dr. Alex Kentsis, MD, PhD.
Analysts’ Opinion of SLS
Many brokerage firms have already submitted their reports for SLS stocks, with Cantor Fitzgerald repeating the rating for SLS by listing it as a “Overweight”. The predicted price for SLS in the upcoming period, according to Cantor Fitzgerald is $18 based on the research report published on July 21, 2021 of the previous year 2021.
Maxim Group gave a rating of “Buy” to SLS, setting the target price at $13 in the report published on March 19th of the previous year.
SLS Trading at 27.60% from the 50-Day Moving Average
After a stumble in the market that brought SLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.37% of loss for the given period.
Volatility was left at 8.41%, however, over the last 30 days, the volatility rate increased by 10.68%, as shares surge +33.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +65.65% upper at present.
During the last 5 trading sessions, SLS rose by +11.28%, which changed the moving average for the period of 200-days by +66.92% in comparison to the 20-day moving average, which settled at $1.79. In addition, SELLAS Life Sciences Group Inc saw 93.75% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SLS starting from VAN NOSTRAND ROBERT L, who purchase 10,000 shares at the price of $1.48 back on Jun 12 ’25. After this action, VAN NOSTRAND ROBERT L now owns 20,400 shares of SELLAS Life Sciences Group Inc, valued at $14,800 using the latest closing price.
Wasman Jane, the Director of SELLAS Life Sciences Group Inc, purchase 20,000 shares at $1.69 during a trade that took place back on May 30 ’25, which means that Wasman Jane is holding 30,400 shares at $33,800 based on the most recent closing price.
Stock Fundamentals for SLS
The total capital return value is set at -1.0%. Equity return is now at value -144.90%, with -91.36% for asset returns.
Based on SELLAS Life Sciences Group Inc (SLS), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -38.75.
Currently, EBITDA for the company is -30.88 million with net debt to EBITDA at 0.99. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.64.
Conclusion
To put it simply, SELLAS Life Sciences Group Inc (SLS) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
